You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

52 Results
Guidelines and Advice
Status: Current
ID: GL-C50-20
May 2015
Drug
Other Name(s): Provera® (multiple brands available)
Apr 2015
Guidelines and Advice
Jan 2015
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Palliative
Mar 2020
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant, Curative, Palliative
Mar 2020
Guidelines and Advice
Status: Current
ID: GL 2-30a
Version: N/A
Mar 2020
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Mar 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    dexamethasone
Mar 2020
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Palliative
Mar 2020
Statistical Reports

Pages